Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
T-cell receptor alpha-beta+ CD19+ depleted allogeneic peripheral blood-derived hematopoietic stem cells
- Development stage
- Unknown
- Lead developer
- Istituto Giannina Gaslini
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intravenous
01
Overview
T-cell receptor alpha-beta+ CD19+ depleted allogeneic peripheral blood-derived hematopoietic stem cells is an advanced cellular therapy product developed by the IRCCS Istituto Giannina Gaslini for the treatment of high-risk neuroblastoma and other pediatric malignancies. The therapy utilizes a sophisticated graft engineering process to selectively remove αβ+ T cells, which are the primary mediators of Graft-versus-Host Disease (GvHD), and CD19+ B cells, which are associated with post-transplant Epstein-Barr virus (EBV) complications. By retaining γδ+ T cells and Natural Killer (NK) cells, the graft maintains a strong graft-versus-tumor effect and provides early protection against infections. This approach allows for successful HLA-haploidentical hematopoietic stem cell transplantation (HSCT) in children who lack a matched donor, offering a curative option with significantly reduced transplant-related morbidity.
- Other names
- TCRαβ+/CD19+ depleted allogeneic HSCTalpha/beta T-cell and B-cell depleted hematopoietic stem cell transplantationalpha/beta T-cell and CD19+ B-cell depleted haploidentical HSCTTCR alpha/beta and CD19 depleted peripheral blood stem cells
02
Targets
CD19 (B lymphocyte antigen CD19)TCR (T cell antigen receptor complex)
Beyond the preview
Go deeper on T-cell receptor alpha-beta+ CD19+ depleted allogeneic peripheral blood-derived hematopoietic stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on T-cell receptor alpha-beta+ CD19+ depleted allogeneic peripheral blood-derived hematopoietic stem cells.